Preventative treatment with NovoEight reduces bleeding in hemophilia A

Danish insulin giant Novo Nordisk (NOV: N) has announced new Phase III interim data from its guardianT2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight (turoctocog alfa) which shows that it provides long-term reduction from bleeding in people with hemophilia A when used as a preventative treatment.

The results were presented at the World Federation of Hemophilia (WFH) World Congress and support findings from other studies within the guardianT clinical program that found NovoEight demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients. NovoEight uses advanced protein and purification technology to provide a reliable and portable treatment option for people with haemophilia A combined with a good safety profile.

Margareth Ozelo guardianT2 investigator said: “As a physician treating hemophilia A, having another FVIII product available is good news and can lead to improved treatment outcomes and quality of life for our patients. Reducing the number of bleeding episodes is a key consideration as they are very painful and frightening for patients and caregivers and can lead to severe long-term joint damage or arthropathy.”